



NDA 208019/S-008

APPROVAL LETTER

Genus Lifesciences Inc.
Attention: Demeitrius Sawickij
Vice President of Regulatory Affairs
514 North 12th Street
Allentown, PA 18102

Dear Demeitrius Sawickij:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 16, 2025, and your amendments, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Pokonza (potassium chloride) powder for solution.

This Prior Approval supplemental new drug application provides for addition of 15 mEq strength of Potassium Chloride powder for Oral Solution under the proprietary name POKONZA.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels and carton and container labels submitted on October 18, 2024, for the 10 mEq, Sample Carton label, 4 count, July 16, 2025, for the 15 mEq Retail Container label, October 21, 2025, for the 15 mEq, Sample Carton label, 4 count, 15 mEq, Retail Carton label, 30 count, 15 mEq, Retail Carton label, 60 count, 10 mEq, Pouch Sample Container label, and the 15 mEq, Pouch Sample Container label as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 208019/S-008.**” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

COMPENDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP’s website¹.

¹ <https://www.uspnf.com/>

If you have any questions, contact Erica Keafer, Regulatory Business Process Manager, at (301) 796 – 1435 or erica.keafer@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Joyce Crich, Ph.D.
Senior Pharmaceutical Quality Assessor

For:
Vilayat Sayeed, Ph.D.
Director
Division of Product Quality Assessment II
Office of Product Quality Assessment I
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):

- Content of Labeling
 - Prescribing Information
- Carton and Container Labeling



Joyce
Crich

Digitally signed by Joyce Crich

Date: 11/12/2025 05:16:32PM

GUID: 5058dd5000000681be093e8cc380aa3f